Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma (CSCC) accounts for approximately 20% of all keratinocytic tumors. In most cases, the diagnosis and treatments are made on small, low-risk lesions. However, in about 5% of cases, CSCC may present as either locally advanced or metastatic (i.e. with locoregional lymph...

Full description

Bibliographic Details
Main Authors: Andrea Boutros, Federica Cecchi, Enrica Teresa Tanda, Elena Croce, Riccardo Gili, Luca Arecco, Francesco Spagnolo, Paola Queirolo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
skin cancer
CSCC
cutaneous squamous cell carcinoma
cemiplimab
non-melanoma skin cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.733917/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.733917/full

Similar Items